IT services company Zensar Technologies has granted in-principle approval to merge two of its US-based step-down subsidiaries—Bridgeview Life Sciences LLC and M3BI LLC—into its material wholly owned subsidiary, Zensar Technologies Inc., USA, as part of a group restructuring aimed at improving operational efficiency.
“We wish to inform you that the Board of Directors of the Company at its meeting held on July 29, 2026, has accorded in-principle approval for the merger of the following US-based step-down subsidiary(ies) of the Company into Zensar Technologies Inc., USA, a material wholly owned subsidiary of the Company, either directly or indirectly,” said Zensar Technologies Limited in its regulatory filing.
The company’s board approved the proposal at its meeting held on July 29. The merger may be executed either directly or indirectly through the incorporation of a new entity to facilitate the transaction, Zensar said in a regulatory filing.
The proposal is subject to approval by the boards and shareholders of the respective merging entities as well as Zensar Technologies Inc. Upon completion of the transaction, Bridgeview Life Sciences LLC and M3BI LLC will cease to exist as step-down subsidiaries of the listed company.
Zensar said the restructuring is intended to achieve greater business synergies, improve operational efficiencies, and enable more effective management through unified control of operations.
As of March 31, 2026, Bridgeview Life Sciences reported a net worth of $0.4 million and turnover of $4.74 million, while M3BI had a net worth of $9.32 million and turnover of $46.8 million. Zensar Technologies Inc., the surviving entity, reported a net worth of $74.66 million and turnover of $326.96 million.
